Cancer risk with calcium-channel-blocker use examined.
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects*; D002121:Calcium Channel Blockers / Q000009:adverse effects*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D009369:Neoplasms / Q000139:chemically induced*; D018570:Risk Assessment
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D002121:Calcium Channel Blockers